The first patient in Hong Kong has been treated with the Diamondback 360 coronary Orbital Atherectomy System (Cardiovascular Systems). A press release reports that this procedure marks the first international coronary procedure taking place as a result of the company’s distribution agreement with OrbusNeich.
Michael Kang-Yin Lee (Queen Elizabeth Hospital, Hong Kong, China), says: “Orbital Atherectomy is simple to use. It is a very controllable and predictable atherectomy device and is especially useful for diffuse and severely calcified coronary arteries, ensuring the angioplasty procedures can be completed with ease and good results. OAS also helps to fill the gap of the conventional devices when treating calcified coronary arteries.”
Scott Ward, chairman, president and CEO of CSI, comments: “We are thrilled to begin introducing our proven coronary atherectomy technology to physicians worldwide. As our international distribution partner, OrbusNeich, identifies new markets, we are prepared to provide best-in-class training to physicians committed to improving patient outcomes within this under-served patient population.”
In July 2018, CSI announced that it had signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside of the USA and Japan.
In January 2018, CSI announced that it was the exclusive US distributor for OrbusNeich balloon products. Ultimately, CSI will offer a full line of semi-compliant, non-compliant and specialty balloons for both coronary and peripheral vascular procedures. OrbusNeich percutaneous coronary intervention (PCI) balloons include the Sapphire II Pro, the first and only 1mm coronary balloon available in the USA.